Product/Composition:- | Rituximab |
---|---|
Strength:- | IV infusion: 100 mg/10 mL, 500 mg/50 mL; SQ: 1400 mg/11 mL |
Form:- | IV Infusion; Subcutaneous |
Reference Brands:- | Rituxan®(US), MabThera®, Truxima®(EU);Ruxience®(US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Rituximab is a monoclonal antibody used to treat hematologic cancers and autoimmune diseases. It targets CD20 on B cells for cell destruction. Available as Rituxan® (US) and MabThera® (EU), Rituximab is offered in IV infusion and subcutaneous forms. Manufactured under GMP standards, it is a trusted option for oncology and autoimmune disease treatment, making it a reliable choice for pharmaceutical distributors across EU and US markets.
Rituximab is a monoclonal antibody used for treating various hematologic cancers and autoimmune disorders. It targets CD20 on B cells, facilitating their destruction, and is effective for conditions such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. Available under Rituxan® in the US and MabThera® in the EU, Rituximab is supplied in IV infusion (100 mg/10 mL, 500 mg/50 mL) and subcutaneous (1400 mg/11 mL) formulations. Manufactured in GMP-compliant facilities, Rituximab is a trusted treatment option for oncology and autoimmune disease management, offering reliable solutions for pharma distributors across EU and US markets.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications